These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 25248002)

  • 1. eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis.
    Pedersen N; Thielsen P; Martinsen L; Bennedsen M; Haaber A; Langholz E; Végh Z; Duricova D; Jess T; Bell S; Burisch J; Munkholm P
    Inflamm Bowel Dis; 2014 Dec; 20(12):2276-85. PubMed ID: 25248002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E-health: Web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance.
    Elkjaer M
    Dan Med J; 2012 Jul; 59(7):B4478. PubMed ID: 22759851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EHealth: self-management in inflammatory bowel disease and in irritable bowel syndrome using novel constant-care web applications. EHealth by constant-care in IBD and IBS.
    Pedersen N
    Dan Med J; 2015 Dec; 62(12):B5168. PubMed ID: 26621403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis.
    Yamamoto T; Shimoyama T; Matsumoto K
    Aliment Pharmacol Ther; 2015 Sep; 42(5):549-58. PubMed ID: 26140337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment.
    Elkjaer M; Burisch J; Avnstrøm S; Lynge E; Munkholm P
    Eur J Gastroenterol Hepatol; 2010 Jun; 22(6):695-704. PubMed ID: 19543101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methodological Approach to Mesalazine Treatment in Patients with Mild-to-moderate Ulcerative Colitis.
    Agilli M; Dogan T; Ergin G
    Inflamm Bowel Dis; 2015 Aug; 21(8):E14-5. PubMed ID: 26083615
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to Methodological Approach to Mesalazine Treatment in Patients with Mild-to-moderate Ulcerative Colitis.
    Pedersen N; Munkholm P
    Inflamm Bowel Dis; 2015 Aug; 21(8):E15-6. PubMed ID: 26111214
    [No Abstract]   [Full Text] [Related]  

  • 8. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.
    Sandborn WJ; Kamm MA; Lichtenstein GR; Lyne A; Butler T; Joseph RE
    Aliment Pharmacol Ther; 2007 Jul; 26(2):205-15. PubMed ID: 17593066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence, risk factors of non-adherence and patient's preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study.
    Keil R; Wasserbauer M; Zádorová Z; Kojecký V; Hlava Š; Št'ovíček J; Chudý J; Roznětinská M; Drábek J; Kubišová N; Lochmannová J
    Scand J Gastroenterol; 2018 Apr; 53(4):459-465. PubMed ID: 29560753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
    Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
    Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesalazine dose modification based on faecal calprotectin levels in patients with ulcerative colitis in clinical remission.
    Piñero G; Mañosa M; Calafat M; Vayreda E; Cañete F; Puig M; Domènech E
    Gastroenterol Hepatol; 2024; 47(6):612-619. PubMed ID: 37806344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study.
    Hyams JS; Davis S; Mack DR; Boyle B; Griffiths AM; LeLeiko NS; Sauer CG; Keljo DJ; Markowitz J; Baker SS; Rosh J; Baldassano RN; Patel A; Pfefferkorn M; Otley A; Heyman M; Noe J; Oliva-Hemker M; Rufo P; Strople J; Ziring D; Guthery SL; Sudel B; Benkov K; Wali P; Moulton D; Evans J; Kappelman MD; Marquis A; Sylvester FA; Collins MH; Venkateswaran S; Dubinsky M; Tangpricha V; Spada KL; Britt A; Saul B; Gotman N; Wang J; Serrano J; Kugathasan S; Walters T; Denson LA
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):855-868. PubMed ID: 28939374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
    Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M
    Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
    D'Haens G; Hommes D; Engels L; Baert F; van der Waaij L; Connor P; Ramage J; Dewit O; Palmen M; Stephenson D; Joseph R
    Aliment Pharmacol Ther; 2006 Oct; 24(7):1087-97. PubMed ID: 16984503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis.
    Kamm MA; Lichtenstein GR; Sandborn WJ; Schreiber S; Lees K; Barrett K; Joseph R
    Gut; 2008 Jul; 57(7):893-902. PubMed ID: 18272546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial.
    Rubin DT; Bradette M; Gabalec L; Dobru D; Márquez J; Inglis S; Magee E; Solomon D; D'Haens G;
    J Crohns Colitis; 2016 Aug; 10(8):925-33. PubMed ID: 26908939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life.
    Probert CS; Dignass AU; Lindgren S; Oudkerk Pool M; Marteau P
    J Crohns Colitis; 2014 Mar; 8(3):200-7. PubMed ID: 24012063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.
    Flourié B; Hagège H; Tucat G; Maetz D; Hébuterne X; Kuyvenhoven JP; Tan TG; Pierik MJ; Masclee AA; Dewit O; Probert CS; Aoucheta D;
    Aliment Pharmacol Ther; 2013 Apr; 37(8):767-75. PubMed ID: 23451806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients.
    Solomon D; Yarlas A; Hodgkins P; Karlstadt R; Yen L; Kane S
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1386-96. PubMed ID: 22536781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of third-party reporting on adoption of evidence-based mesalazine regimens in ulcerative colitis: an observational study.
    Kruis W; Leifeld L; Morgenstern J; Pfützer R; Reimers B; Ceplis-Kastner S;
    J Crohns Colitis; 2013 May; 7(4):e125-32. PubMed ID: 22951030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.